Contact Us
Menu
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Events
News
Posts

AACR 2024 Posters

Home News & Resources Events AACR 2024 Posters

AACR 2024 Posters

We are thrilled to have had the opportunity to attend the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA. Your interest in our research progress and the insightful discussions we had about your projects and objectives truly made our experience at AACR memorable. These exchanges are invaluable in advancing our collective efforts in cancer research.

Below, you will find all of the poster presentations from the conference available for download!

 

AACR 2024 Poster Presentations

Off-the-Shelf Mouse Model Posters

Target Related Model  Poster Title (click to download)
VEGFA B-hVEGFA mice Development of humanized VEGFA models to assess preclinical efficacy of novel therapeutics in vivo
TL1A B-hTL1A mice Validation of humanized TL1A mice for advancing preclinical research
B-hCD3EDG/h4-1BB B-hCD3EDG/h4-1BB mice Establishment of humanized CD3EDG/4-1BB mice for testing novel T cell engagers
IL31/IL31RA/OSM/OSMR B-hIL31/hIL31RA/hOSM/hOSMR mice Generation and validation of a novel humanized IL-31/IL-31RA/OSM/OSMR mouse model
PD-1/PD-L1/CD94/NKG2A B-hPD-1/hPD-L1/hCD94/hNKG2A mice Generation of humanized PD-1/PD-L1/CD94/NKG2A mice for evaluating novel combination therapies
PD-1/PD-L1 B-hPD-1/hPD-L1 mice TIL analysis demonstrates different mechanisms underlying PD-1 resistance in animal models
IL5/IL5RA B-hIL5/hIL5RA mice Establishment of a humanized IL5/IL5RA mouse model to evaluate modulators of eosinophilic inflammation in vivo
NKP46 B-hNKP46 mice A novel humanized NKP46 mouse model to support xenograft studies evaluating NK cell-based cancer immunotherapies
RAG2/IL2RG B-SDG rats Generation of a novel severely immunodeficient Sprague Dawley rat model for xenograft studies
B2M/HLA-A11.1/HLA-A24.2 B-HLA-A11.1 mice

B-HLA-A24.2 mice

 Development and validation of humanized HLA mouse model platforms for preclinical evaluation of novel peptide therapeutics
CD16A B-hCD16A (CB-17 SCID) mice A novel humanized CD16A model to evaluate efficacy of human antibody therapeutics in triggering ADCC

RenMabTM-Based Fully Human Antibody Assets

RenLite®-derived Fully Human BsAb and BsADC Assets

Targets Platform Poster Title (click to download)
FOLR1/MUC1 BsAb Discovery Platform A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model
EGFR/CD70 BsAb Discovery Platform BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors
HER3/MET BsAb Discovery Platform BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy
5T4/MUC1 Bispecific ADC Platform BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity
PTK7/TROP2 Bispecific ADC Platform BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts
PTK7/EGFR Bispecific ADC Platform BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models
EGFR/HER3 Bispecific ADC Platform A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

TCR-Mimic Antibody Assets

 

 

Several collaborators of our RenBiologics Division presented at AACR 2024:

 

Syncromune’s Oral Presentation:

Our therapeutic antibody collaborator Syncromune delivered an oral presentation unveiling clinical data of its SYNC-T technology for the first time! The preliminary clinical results of SYNC-T SV-102, which features our clinical-stage CTLA-4 monoclonal antibody YH001 and CD40 agonistic monoclonal antibody YH003, have showcased an exceptional 85% overall response rate among patients battling metastatic castrate-resistant prostate cancer.

AACR News Release | GlobeNewswire | AACR2024 Abstract

 

CtM Bio’s Poster Presentation

Title: A novel tri-specific T cell engager targeting the intracellular oncoprotein WT1

AACR2024 Abstract

 

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world. (Source: AACR)

Event Date: April 7-10, 2024 | Event Location: San Diego, CA

Share:

    Back to top